Advanced prostate cancer patient and bioinformatician Rick Stanton introduced the treatment options he and his medical team are considering, using the standard (NCCN) treatment guidelines as a way to tell the story of how he got here. This built on Rick’s previous session (see the notes from meeting #6 here), in which he walked through his and Brian McCloskey’s medical history. We have discussed potential enhancements to the guidelines, such as:
- Bring testing forward in the guidelines to help people at each decision point.
- Embed more real world evidence in the decisions.
- Add more structure and explicit guidance for decisions in the late stages.
- Make the guidelines more dynamic and predictive.
- Put a treatment strategy with guiding principles on top of it.
Based on the test results and his medical history, Rick and his medical team have identified this list of treatment options:
- Pluvicto (radioligand attacking PSMA, currently unavailable due to production issues)
- Olaparib (targeting CDK12) + CTLA4 inhibitor + PDL1 blockade
- PSMA CAR-T from Poseida (targeting PSMA)
- PSMA bispecific from Calibr (targeting PSMA)
- ASRV-766 AR degrader (targeting AR)
- Daiichi antibody drug conjugate to B7-H3 (targeting B7-H3)
- Cabazitaxel (chemotherapy)
Do you have any feedback on Rick’s testing and treatment options?